drugset / Trial / NCT02029430

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

NCT02029430

Phase 2 Completed 15 enrolled ImmunityBio, Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.

Timeline

Start
2014-04-03
Primary completion
2016-04-25
Completion
2016-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Aldoxorubicin Small molecule 50 mg/m2
Subject Aldoxorubicin Small molecule 100 mg/m2
Subject Aldoxorubicin Small molecule 150 mg/m2

Indications